Pirarubicin is a new anthracycline anticancer agent structurally related to doxorubicin. In acute leukemia, non-Hodgkin’s lymphoma, breast and ovariail carcinoma, pirarubicin is reportedly superior to doxorubicin and better tolerated. Its major side-effect appears to be myelosuppression, mainly in the form of leucopenia, which is potentially dose-limiting.
3.Melting point:188-192°C (dec.)
7.Boiling point:834.7°C at 760 mmHg
1.This product have remarkable curative effect on of acute leukemia, malignant lymphoma, head-and-neck cancer, urothelialcarcinom.
2.Pirarubicin is suitable for the treatment of breast cancer.
3.It is also effective for malignant tumors such as head and neck cancer, bladder cancer, ureteral cancer, renal pelvis cancer, ovarian cancer, cervical cancer and so on. The drug can be directly intercalated into DNA double strands, inhibit DNA polymerase, inhibit nucleic acid synthesis, and prevent cell division in G2 phase, thus leading to the death of tumor cells.